Drug Profile

Research programme: recombinant human factor VIII - GTC Biotherapeutics/ProGenetics

Latest Information Update: 16 Jul 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProGenetics
Developer ProGenetics; rEVO Biologics
Class Blood coagulation factors; Recombinant proteins
Mechanism of Action Blood coagulation factor replacements; Factor X stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies
06 Dec 2007 Recombinant human factor VIII, factor IX and fibrinogen licensed to GTC Biotherapeutics in North America, Europe and Japan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com